KÖKahraman Öncel

Kahraman Öncel

*This is an algorithmically generated author record based on publicly available information.

Kahraman Öncel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retrospective analysis of demographic and clinical characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients

    by Murat Solmaz, Murat Söker, Veysiye Hülya Üzel, Sevda Söker, Kahraman Öncel, Kamil Yilmaz

    Aim: This study aimed to compare treatment outcomes (mortality and relapse) between two pediatric acute lymphoblastic leukemia (ALL) protocols (TR-ALL BFM 2000 vs ALL-IC-BFM 2009) and to describe the demographic, clinical, and laboratory characteristics of patients treated at a single center (2010–2015). Methods: We retrospectively reviewed the medical records of 121 children (<18 years) diagnosed with ALL and treated with either TR-ALL BFM 2000 or ALL-IC-BFM 2009. Baseline characteristics, risk group, immunophenotype, protocol, relapse status, and survival status were recorded. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate (p < 0.05). Results: The cohort was 53.7% male, with a mean age at diagnosis of 7.55 ± 3.89 years. B-cell ALL accounted for 78.5% and T-cell ALL for 21.5%. The overall mortality rate was 11.6% (14/121), and relapse occurred in 5.8% (7/121) of patients. Mortality differed by risk group (SRG 6.5%, IRG 7.3%, HRG 23.5%; p = 0.036). Relapse was higher in T-cell ALL than in B-cell ALL (23.1% vs 1.1%; p = 0.001). Compared with ALL-IC-BFM 2009, TR-ALL BFM 2000 was associated with higher mortality (19.2% vs 5.8%; p = 0.022) and relapse (11.5% vs 1.4%; p = 0.019). Conclusion: In this single-center retrospective cohort study, the high-risk group was associated with higher mortality, and the T-cell immunophenotype was associated with higher relapse. Patients treated with ALL-IC-BFM 2009 had lower crude mortality and relapse rates than those treated with TR-ALL BFM 2000; however, these protocol comparisons should be interpreted cautiously, given potential confounding and limited event numbers.


  • Open Access

    Evaluation of 36 Patients with Rare Factor Deficiency

    by Veysiye Hülya Üzel, Kamil Yılmaz, Kahraman Öncel, Suat Tekin, Murat Söker